Routine

Attention deficit hyperactivity disorder (ADHD)

development · Paediatric
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A neurodevelopmental disorder of persistent inattention and/or hyperactivity-impulsivity causing functional impairment across settings and present before age 12. Diagnosis is clinical; management combines behavioural and, where needed, pharmacological measures.

Red flags

  • Cardiac symptoms, syncope or family history of sudden cardiac death before stimulants
  • Emergent suicidal ideation (notably with atomoxetine)
  • Significant growth faltering on treatment
  • New tics, psychosis or severe mood disturbance

Assessment

Differential diagnosis

  • Normal age-appropriate activity level
  • Learning disability or specific learning disorder
  • Autism spectrum disorder
  • Anxiety, depression or trauma/attachment disorder
  • Hearing impairment or absence seizures
  • Sleep disorder (including OSA)
  • Thyroid dysfunction or substance effects

Investigations

  • Symptom and impairment history across at least two settings (home and school)
  • Standardised rating scales (e.g. Conners, SNAP-IV) from parents and teachers
  • Developmental, family, sleep and mental health history
  • Baseline height, weight, pulse and blood pressure before stimulants
  • Hearing/vision screen and exclusion of absence seizures if suspected
  • Cardiac history and ECG only if cardiac red flags or family history of sudden death

Management

  • Confirm symptoms cause impairment in 2+ settings and predate age 12
  • Collect multi-informant rating scales and school information
  • Exclude mimics (sleep, hearing, anxiety, seizures, learning disorder)
  • Provide psychoeducation and first-line behavioural/parent-training support
  • Record baseline height, weight, pulse and BP before any medication
  • Start stimulant (methylphenidate first line) if impairment persists and titrate to effect
  • Monitor growth, cardiovascular parameters, appetite, sleep and mood at each review
  • Switch to lisdexamfetamine or non-stimulant (atomoxetine/guanfacine) if poor response/tolerability
  • Coordinate school support and review need for ongoing treatment periodically

Drugs & doses

Methylphenidate immediate-release 5 mg PO once-twice daily, titrate to ~0.5-1 mg/kg/dose (modified-release preferred for adherence)
Lisdexamfetamine 30 mg PO once daily (second-line stimulant, titrate by response)
Atomoxetine 0.5 mg/kg/day PO initially, increase to target ~1.2 mg/kg/day (max 1.8 mg/kg or 100 mg)
Guanfacine modified-release 1 mg PO once daily, titrate ~0.05-0.12 mg/kg/day

Disposition

Specialist (paediatric or CAMHS) diagnosis and medication initiation; shared-care monitoring with primary care and school.

Complications & pitfalls

  • Academic underachievement and school exclusion
  • Low self-esteem, anxiety and depression
  • Accidental injury and, later, substance misuse
  • Stimulant effects: appetite/growth suppression, insomnia, raised BP/pulse

Exam pearls

  • Diagnosis requires impairment across settings, not just at home or school alone
  • Plot growth and monitor BP/pulse at every medication review
  • A stimulant drug holiday can be considered if growth suppression is marked
  • Treat coexisting sleep disorder and anxiety as they amplify symptoms

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.